Werewolf Therapeutics (NASDAQ:HOWL) Issues Quarterly Earnings Results

Werewolf Therapeutics (NASDAQ:HOWL) posted its quarterly earnings results on Friday. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02, FiscalAI reports.

Werewolf Therapeutics Stock Up 0.0%

NASDAQ:HOWL traded up $0.00 on Friday, hitting $0.98. The stock had a trading volume of 317,108 shares, compared to its average volume of 2,348,221. Werewolf Therapeutics has a 52 week low of $0.27 and a 52 week high of $1.20. The business’s fifty day moving average is $0.98 and its 200 day moving average is $0.70. The company has a market cap of $47.64 million, a PE ratio of -1.29 and a beta of 0.55.

Wall Street Analyst Weigh In

Several brokerages have recently commented on HOWL. Weiss Ratings raised shares of Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 10th. Zacks Research downgraded shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 3rd. Finally, Wall Street Zen raised shares of Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 22nd. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Werewolf Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $4.00.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cancer treatments that stimulate the immune system. The company’s approach is designed to activate immune responses within the tumor microenvironment while limiting exposure to healthy tissues. Werewolf’s technology platform, known as INDUKINE, uses conditionally activated cytokines. These therapeutic proteins are intended to remain inactive in the bloodstream and become activated primarily in tumors, where they may help recruit and enhance immune cells to attack cancer.